<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="editorial"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Trop Med Hyg</journal-id><journal-id journal-id-type="iso-abbrev">Am. J. Trop. Med. Hyg</journal-id><journal-id journal-id-type="publisher-id">tpmd</journal-id><journal-title-group><journal-title>The American Journal of Tropical Medicine and Hygiene</journal-title></journal-title-group><issn pub-type="ppub">0002-9637</issn><issn pub-type="epub">1476-1645</issn><publisher><publisher-name>The American Society of Tropical Medicine and Hygiene</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25070994</article-id><article-id pub-id-type="pmc">4155540</article-id><article-id pub-id-type="doi">10.4269/ajtmh.14-0395</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>The Ability to Inoculate Purified Malaria Sporozoites Will Accelerate Vaccine and Drug Discovery</article-title><alt-title alt-title-type="left-running-head">GOOD</alt-title><alt-title alt-title-type="right-running-head">EDITORIAL</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Good</surname><given-names>Michael F.</given-names></name><xref ref-type="corresp" rid="COR1">*</xref></contrib></contrib-group><aff id="AFF1">Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australia</aff><author-notes><corresp id="COR1">*Address correspondence to Michael F. Good, G26, 4.18, Institute for Glycomics, Griffith University, Gold Coast, QLD, Australia 4222. E-mail: <email>michael.good@griffith.edu.au</email></corresp></author-notes><pub-date pub-type="ppub"><day>03</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>03</day><month>9</month><year>2014</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. --><volume>91</volume><issue>3</issue><fpage>437</fpage><lpage>438</lpage><history><date date-type="received"><day>25</day><month>6</month><year>2014</year></date><date date-type="accepted"><day>25</day><month>6</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9;The American Society of Tropical Medicine and Hygiene</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions></article-meta></front><body><p>The ability to infect a volunteer with malaria in a controlled and safe manner promises to be of enormous benefit to research programs aimed at developing malaria vaccines<xref rid="R1" ref-type="bibr">1</xref> or novel antimalaria drugs.<xref rid="R2" ref-type="bibr">2</xref> By challenging an individual in early-stage trials with a defined number of parasites of a specific laboratory strain in a controlled clinical environment, it is possible to derive more meaningful data and significantly reduce trial costs, thus facilitating product development. Research presented in this issue shows that it will now be possible for trial volunteers living in both malaria-endemic and non-endemic areas.<xref rid="R3" ref-type="bibr">3</xref></p><p>An early breakthrough occurred in 1986, when Chulay and others<xref rid="R4" ref-type="bibr">4</xref> showed that malaria could be transmitted to na&#x000ef;ve volunteers by mosquitoes previously fed on cultured gametocytes. In that study, the volunteers, who had never been exposed to malaria, developed a patent infection 7&#x02013;11 days post-feeding.<xref rid="R4" ref-type="bibr">4</xref> The study was a significant advance on previous approaches, in which malaria had been transmitted by mosquitoes deliberately fed on infected volunteers.<xref rid="R5" ref-type="bibr">5</xref> However, as noted in the 1973 study,<xref rid="R5" ref-type="bibr">5</xref> a concern relevant to both approaches was that it was impossible to determine the number of sporozoites that were injected by the mosquitoes. It was not technically possible at that time to develop a purified population of sporozoites that could be injected in a reproducible manner by syringe. This challenge lay dormant for some time, but in 2002, scientists at Sanaria commenced a major project to develop a technology to mechanically prepare sporozoites from infected mosquitoes. This technology would enable the safe infection of volunteers with defined numbers of organisms and could also be used to develop an irradiated whole-parasite vaccine (reviewed in ref.<xref rid="R6" ref-type="bibr">6</xref>). Now, after more than a decade of research, there have been three recent reports of individuals developing malaria post-inoculation of aseptic, purified, cryopreserved <italic>Plasmodium falciparum</italic> sporozoites.<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref> The latest report, in this issue,<xref rid="R3" ref-type="bibr">3</xref> describes the first deliberate inoculation of individuals from a malaria-endemic area.</p><p>In the first study (involving healthy Dutch volunteers),<xref rid="R7" ref-type="bibr">7</xref> it was shown that purified aseptic sporozoites could be administered to volunteers with a safety profile similar to mosquito bite challenge. Adverse events were attributable only to malaria and not the inoculation <italic>per se</italic>. Volunteers (six per group) received 2,500, 10,000, or 25,000 sporozoites injected intradermally. Of 18 recipients, 15 recipients developed a blood-stage malaria infection. In the next study,<xref rid="R8" ref-type="bibr">8</xref> 14 of 18 healthy malaria-na&#x000ef;ve volunteers living in the United Kingdom developed malaria after intradermal or intramuscular inoculation of sporozoites. In the latest study from Tanzania, 21 of 23 adult volunteers who had previously experienced malaria were infected after intradermal inoculation of 10,000 or 25,000 sporozoites.<xref rid="R3" ref-type="bibr">3</xref> Infections were confirmed by microscopy and polymerase chain reaction (PCR), and heterozygosity for &#x003b1;-thalassemia (highly prevalent in that area) did not affect the infectivity rates.</p><p>However, these infectivity studies raise some important issues that may need to be considered to optimize this approach. Across all three studies, only 84% of individuals became infected after inoculation with up to 25,000 sporozoites (although if intramuscular inoculation is excluded, this percentage increases slightly). Why is the infectivity not 100%? By comparison, more than 95% of volunteers routinely became infected after the bites of five infected mosquitoes,<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref> although the mean number of sporozoites inoculated per mosquito may be as low as 120.<xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R12" ref-type="bibr">12</xref> Thus, sporozoites delivered by mosquito inoculation would seem to be significantly more infective than cryopreserved sporozoites delivered by syringe. It seems likely that this finding is because of the small volumes that mosquitoes inject that prevent degradation of organisms at the center of a large bolus injection, their method of inoculation, and the enhanced viability of fresh compared with cryopreserved organisms. If these differences between mosquito and syringe inoculation could be partially rectified, it is likely that significantly enhanced infectivity will be observed after syringe inoculation and thus, increase the use of this approach.</p><p>Some important lessons to address these issues can be gleaned from sporozoite infectivity studies in rodents. Ploemen and others<xref rid="R13" ref-type="bibr">13</xref> showed that infectivity rates of <italic>P. yoelii</italic> sporozoites in mice after syringe inoculation decreased as the inoculation volume increased. The study by Shekalaghe and others<xref rid="R3" ref-type="bibr">3</xref> lends support to this finding for <italic>P. falciparum</italic> by comparing the pre-patent period in individuals who received sporozoites in a volume of 50 &#x003bc;L with those who received sporozoites in a volume of only 10 &#x003bc;L. Although it may be difficult to reduce volumes for intradermal inoculation much farther, it would seem appropriate to consider intravenous inoculation as an alternative strategy. For example, the infectivity of <italic>P. yoelii</italic> sporozoites increases by more than 20-fold when delivered through the intravenous route compared with the intradermal route.<xref rid="R7" ref-type="bibr">7</xref> Furthermore, there are no apparent safety considerations to administering sporozoites by the intravenous route.<xref rid="R10" ref-type="bibr">10</xref></p><p>Sporozoite viability after cryopreservation is likely to be another factor affecting infectivity. Using the rodent model of <italic>P. yoelii</italic>, the infectivity of cryopreserved sporozoites was reduced by more than a factor of seven compared with fresh sporozoites when both were injected intravenously.<xref rid="R7" ref-type="bibr">7</xref> If parasite viability could be increased, then the operational constraints around production of organisms at scale would be greatly diminished.</p><p>However, the technological significance of these developments to date cannot be overstated. They will allow routine challenge of individuals receiving various experimental vaccines or drugs to determine efficacy. Furthermore, they will allow for accelerated development of an irradiated sporozoite vaccine. Until recently, the most significant level of induced immunological protection from malaria was observed in volunteers exposed to the bites of over 1,000 irradiated infected mosquitoes. From the aggregates of different studies, over 90% of immunized volunteers could be protected from malaria. These data were both extremely encouraging but also frustrating in that irradiated mosquitoes could never be considered as a vaccine. However, data published in 2011 and 2013<sup>9,10</sup> showed that irradiated cryopreserved sporozoites could induce immunity in a dose-dependent manner. These early encouraging vaccine results have only been possible as a result of the advances in gametocyte culture, entomological husbandry, sporozoite preparation, and cryobiology. Thus, the developments reported here and over the last 3 years may represent a watershed moment in malaria research.</p></body><back><fn-group><fn id="FN1" fn-type="present-address"><p>Author's address: Michael F. Good, Institute for Glycomics, Griffith University, Gold Coast, QLD, Australia, E-mail: <email>michael.good@griffith.edu.au</email>.</p></fn></fn-group><ref-list><ref id="R1"><label>1.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hill</surname><given-names>AVS</given-names></name></person-group>
<year>2011</year>
<article-title>Vaccines against malaria</article-title>
<source>Philos Trans R Soc Lond B Biol Sci</source>
<volume>366</volume>
<fpage>2806</fpage>
<lpage>2814</lpage><pub-id pub-id-type="pmid">21893544</pub-id></element-citation></ref><ref id="R2"><label>2.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>TA</given-names></name><name><surname>Ranasinha</surname><given-names>CD</given-names></name><name><surname>Kumar</surname><given-names>N</given-names></name><name><surname>Barditch-Crovo</surname><given-names>P</given-names></name></person-group>
<year>1999</year>
<article-title>Prophylactic activity of atovaquone against <italic>Plasmodium falciparum</italic> in humans</article-title>
<source>Am J Trop Med Hyg</source>
<volume>60</volume>
<fpage>831</fpage>
<lpage>836</lpage><pub-id pub-id-type="pmid">10344660</pub-id></element-citation></ref><ref id="R3"><label>3.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shekalaghe</surname><given-names>S</given-names></name><name><surname>Rutaihwa</surname><given-names>M</given-names></name><name><surname>Billingsley</surname><given-names>PF</given-names></name><name><surname>Chemba</surname><given-names>M</given-names></name><name><surname>Daubenberger</surname><given-names>CA</given-names></name><name><surname>James</surname><given-names>E</given-names></name><name><surname>Mpina</surname><given-names>M</given-names></name><name><surname>Ali Juma</surname><given-names>O</given-names></name><name><surname>Schindler</surname><given-names>T</given-names></name><name><surname>Huber</surname><given-names>E</given-names></name><name><surname>Gunasekera</surname><given-names>A</given-names></name><name><surname>Manoj</surname><given-names>A</given-names></name><name><surname>Simon</surname><given-names>B</given-names></name><name><surname>Savarino</surname><given-names>E</given-names></name><name><surname>Church</surname><given-names>LWP</given-names></name><name><surname>Hermsen</surname><given-names>CC</given-names></name><name><surname>Sauerwein</surname><given-names>RW</given-names></name><name><surname>Plowe</surname><given-names>C</given-names></name><name><surname>Venkatesan</surname><given-names>M</given-names></name><name><surname>Sasi</surname><given-names>P</given-names></name><name><surname>Lweno</surname><given-names>O</given-names></name><name><surname>Mutani</surname><given-names>P</given-names></name><name><surname>Hamad</surname><given-names>A</given-names></name><name><surname>Mohammed</surname><given-names>A</given-names></name><name><surname>Urassa</surname><given-names>A</given-names></name><name><surname>Mzee</surname><given-names>T</given-names></name><name><surname>Padilla</surname><given-names>D</given-names></name><name><surname>Ruben</surname><given-names>A</given-names></name><name><surname>Sim</surname><given-names>BKL</given-names></name><name><surname>Tanner</surname><given-names>M</given-names></name><name><surname>Abdullah</surname><given-names>S</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name></person-group>
<year>2014</year>
<article-title>Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved <italic>Plasmodium falciparum</italic> sporozoites</article-title>
<source>Am J Trop Med Hyg</source>
<volume>91</volume>
<fpage>471</fpage>
<lpage>480</lpage><pub-id pub-id-type="pmid">25070995</pub-id></element-citation></ref><ref id="R4"><label>4.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chulay</surname><given-names>JD</given-names></name><name><surname>Schneider</surname><given-names>I</given-names></name><name><surname>Cosgriff</surname><given-names>TM</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name><name><surname>Ballou</surname><given-names>WR</given-names></name><name><surname>Quakyi</surname><given-names>IA</given-names></name><name><surname>Carter</surname><given-names>R</given-names></name><name><surname>Trosper</surname><given-names>JH</given-names></name><name><surname>Hockmeyer</surname><given-names>WT</given-names></name></person-group>
<year>1986</year>
<article-title>Malaria transmitted to humans by mosquitoes infected from cultured <italic>Plasmodium falciparum</italic></article-title>
<source>Am J Trop Med Hyg</source>
<volume>35</volume>
<fpage>66</fpage>
<lpage>68</lpage><pub-id pub-id-type="pmid">3511753</pub-id></element-citation></ref><ref id="R5"><label>5.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clyde</surname><given-names>DF</given-names></name><name><surname>Most</surname><given-names>H</given-names></name><name><surname>McCarthy</surname><given-names>VC</given-names></name><name><surname>Vanderberg</surname><given-names>JP</given-names></name></person-group>
<year>1973</year>
<article-title>Immunization of man against sporozite-induced falciparum malaria</article-title>
<source>Am J Med Sci</source>
<volume>266</volume>
<fpage>169</fpage>
<lpage>177</lpage><pub-id pub-id-type="pmid">4583408</pub-id></element-citation></ref><ref id="R6"><label>6.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>SL</given-names></name><name><surname>Billingsley</surname><given-names>PF</given-names></name><name><surname>James</surname><given-names>E</given-names></name><name><surname>Richman</surname><given-names>A</given-names></name><name><surname>Loyevsky</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Chakravarty</surname><given-names>S</given-names></name><name><surname>Gunasekera</surname><given-names>A</given-names></name><name><surname>Chattopadhyay</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Stafford</surname><given-names>R</given-names></name><name><surname>Ahumada</surname><given-names>A</given-names></name><name><surname>Epstein</surname><given-names>JE</given-names></name><name><surname>Sedegah</surname><given-names>M</given-names></name><name><surname>Reyes</surname><given-names>S</given-names></name><name><surname>Richie</surname><given-names>TL</given-names></name><name><surname>Lyke</surname><given-names>KE</given-names></name><name><surname>Edelman</surname><given-names>R</given-names></name><name><surname>Laurens</surname><given-names>MB</given-names></name><name><surname>Plowe</surname><given-names>CV</given-names></name><name><surname>Sim</surname><given-names>BK</given-names></name></person-group>
<year>2010</year>
<article-title>Development of a metabolically active, non-replicating sporozoite vaccine to prevent <italic>Plasmodium falciparum</italic> malaria</article-title>
<source>Hum Vaccin</source>
<volume>6</volume>
<fpage>97</fpage>
<lpage>106</lpage><pub-id pub-id-type="pmid">19946222</pub-id></element-citation></ref><ref id="R7"><label>7.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roestenberg</surname><given-names>M</given-names></name><name><surname>Bijker</surname><given-names>M</given-names></name><name><surname>Sim</surname><given-names>BK</given-names></name><name><surname>Billingsley</surname><given-names>PF</given-names></name><name><surname>James</surname><given-names>ER</given-names></name><name><surname>Bastiaens</surname><given-names>GJ</given-names></name><name><surname>Teirlinck</surname><given-names>AC</given-names></name><name><surname>Scholzen</surname><given-names>A</given-names></name><name><surname>Teelen</surname><given-names>K</given-names></name><name><surname>Arens</surname><given-names>T</given-names></name><name><surname>van der Ven</surname><given-names>AJ</given-names></name><name><surname>Gunasekera</surname><given-names>A</given-names></name><name><surname>Chakravarty</surname><given-names>S</given-names></name><name><surname>Velmurugan</surname><given-names>S</given-names></name><name><surname>Hermsen</surname><given-names>CC</given-names></name><name><surname>Sauerwein</surname><given-names>RW</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name></person-group>
<year>2013</year>
<article-title>Controlled human malaria infections by intradermal injection of cryopreserved <italic>Plasmodium falciparum</italic> sporozoites</article-title>
<source>Am J Trop Med Hyg</source>
<volume>88</volume>
<fpage>5</fpage>
<lpage>13</lpage><pub-id pub-id-type="pmid">23149582</pub-id></element-citation></ref><ref id="R8"><label>8.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sheehy</surname><given-names>SH</given-names></name><name><surname>Spencer</surname><given-names>AJ</given-names></name><name><surname>Douglas</surname><given-names>AD</given-names></name><name><surname>Sim</surname><given-names>BK</given-names></name><name><surname>Longley</surname><given-names>RJ</given-names></name><name><surname>Edwards</surname><given-names>NJ</given-names></name><name><surname>Poulton</surname><given-names>ID</given-names></name><name><surname>Kimani</surname><given-names>D</given-names></name><name><surname>Williams</surname><given-names>AR</given-names></name><name><surname>Anagnostou</surname><given-names>NA</given-names></name><name><surname>Roberts</surname><given-names>R</given-names></name><name><surname>Kerridge</surname><given-names>S</given-names></name><name><surname>Voysey</surname><given-names>M</given-names></name><name><surname>James</surname><given-names>ER</given-names></name><name><surname>Billingsley</surname><given-names>PF</given-names></name><name><surname>Gunasekera</surname><given-names>A</given-names></name><name><surname>Lawrie</surname><given-names>AM</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name><name><surname>Hill</surname><given-names>AV</given-names></name></person-group>
<year>2013</year>
<article-title>Optimising controlled human malaria infection studies using cryopreserved <italic>P. falciparum</italic> parasites administered by needle and syringe</article-title>
<source>PLoS One</source>
<volume>88</volume>
<fpage>e65960</fpage><pub-id pub-id-type="pmid">23823332</pub-id></element-citation></ref><ref id="R9"><label>9.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Epstein</surname><given-names>JE</given-names></name><name><surname>Chang</surname><given-names>LJ</given-names></name><name><surname>Enama</surname><given-names>ME</given-names></name><name><surname>Zephir</surname><given-names>KL</given-names></name><name><surname>Sarwar</surname><given-names>UN</given-names></name><name><surname>Gordon</surname><given-names>IJ</given-names></name><name><surname>Holman</surname><given-names>LQ</given-names></name><name><surname>James</surname><given-names>ER</given-names></name><name><surname>Billingsley</surname><given-names>PF</given-names></name><name><surname>Gunasekera</surname><given-names>A</given-names></name><name><surname>Richman</surname><given-names>A</given-names></name><name><surname>Chakravarty</surname><given-names>S</given-names></name><name><surname>Manoj</surname><given-names>A</given-names></name><name><surname>Velmurugan</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Ruben</surname><given-names>AJ</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Eappen</surname><given-names>AG</given-names></name><name><surname>Stafford</surname><given-names>RE</given-names></name><name><surname>Plummer</surname><given-names>SH</given-names></name><name><surname>Hendel</surname><given-names>CS</given-names></name><name><surname>Novik</surname><given-names>L</given-names></name><name><surname>Costner</surname><given-names>PJ</given-names></name><name><surname>Medndoza</surname><given-names>FH</given-names></name><name><surname>Saunders</surname><given-names>JG</given-names></name><name><surname>Nason</surname><given-names>MC</given-names></name><name><surname>Richardson</surname><given-names>JH</given-names></name><name><surname>Murphy</surname><given-names>J</given-names></name><name><surname>Davidson</surname><given-names>SA</given-names></name><name><surname>Richie</surname><given-names>TL</given-names></name><name><surname>Sedegah</surname><given-names>M</given-names></name><name><surname>Sutamihardja</surname><given-names>A</given-names></name><name><surname>Fahle</surname><given-names>GA</given-names></name><name><surname>Lyke</surname><given-names>KE</given-names></name><name><surname>Laurens</surname><given-names>MB</given-names></name><name><surname>Roederer</surname><given-names>M</given-names></name><name><surname>Tewari</surname><given-names>K</given-names></name><name><surname>Epstein</surname><given-names>JE</given-names></name><name><surname>Sim</surname><given-names>BK</given-names></name><name><surname>Ledgerwood</surname><given-names>JE</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name><name><surname>312 Study Team</surname><given-names>VRC</given-names></name></person-group>
<year>2011</year>
<article-title>Live attenuated malaria vaccine designed to protect through hepatic CD8+T cell immunity</article-title>
<source>Science</source>
<volume>334</volume>
<fpage>475</fpage>
<lpage>480</lpage><pub-id pub-id-type="pmid">21903775</pub-id></element-citation></ref><ref id="R10"><label>10.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seder</surname><given-names>RA</given-names></name><name><surname>Chang</surname><given-names>LJ</given-names></name><name><surname>Enama</surname><given-names>ME</given-names></name><name><surname>Zephir</surname><given-names>KL</given-names></name><name><surname>Sarwar</surname><given-names>UN</given-names></name><name><surname>Gordon</surname><given-names>IJ</given-names></name><name><surname>Holman</surname><given-names>LA</given-names></name><name><surname>James</surname><given-names>ER</given-names></name><name><surname>Billingsley</surname><given-names>PF</given-names></name><name><surname>Gunasekera</surname><given-names>A</given-names></name><name><surname>Richman</surname><given-names>A</given-names></name><name><surname>Chakravarty</surname><given-names>S</given-names></name><name><surname>Manoj</surname><given-names>A</given-names></name><name><surname>Velmurugan</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Ruben</surname><given-names>AJ</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Eappen</surname><given-names>AG</given-names></name><name><surname>Stafford</surname><given-names>RE</given-names></name><name><surname>Plummer</surname><given-names>SH</given-names></name><name><surname>Hendel</surname><given-names>CS</given-names></name><name><surname>Novik</surname><given-names>L</given-names></name><name><surname>Costner</surname><given-names>PJ</given-names></name><name><surname>Mendoza</surname><given-names>FH</given-names></name><name><surname>Saunders</surname><given-names>JG</given-names></name><name><surname>Nason</surname><given-names>MC</given-names></name><name><surname>Richardson</surname><given-names>JH</given-names></name><name><surname>Murphy</surname><given-names>J</given-names></name><name><surname>Davidson</surname><given-names>SA</given-names></name><name><surname>Richie</surname><given-names>TL</given-names></name><name><surname>Sedegah</surname><given-names>M</given-names></name><name><surname>Sutamihardja</surname><given-names>A</given-names></name><name><surname>Fahle</surname><given-names>GA</given-names></name><name><surname>Lyke</surname><given-names>KE</given-names></name><name><surname>Laurens</surname><given-names>MB</given-names></name><name><surname>Roederer</surname><given-names>M</given-names></name><name><surname>Tewari</surname><given-names>K</given-names></name><name><surname>Epstein</surname><given-names>JE</given-names></name><name><surname>Sim</surname><given-names>BK</given-names></name><name><surname>Ledgerwood</surname><given-names>JE</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name><name><surname>312 Study Team</surname><given-names>VRC</given-names></name></person-group>
<year>2013</year>
<article-title>Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine</article-title>
<source>Science</source>
<volume>341</volume>
<fpage>1359</fpage>
<lpage>1365</lpage><pub-id pub-id-type="pmid">23929949</pub-id></element-citation></ref><ref id="R11"><label>11.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Medica</surname><given-names>DL</given-names></name><name><surname>Sinnis</surname><given-names>P</given-names></name></person-group>
<year>2005</year>
<article-title>Quantitative dynamics of <italic>Plasmodium yoelii</italic> sporozoite transmission by infected anopheline mosquitoes</article-title>
<source>Infect Immun</source>
<volume>73</volume>
<fpage>4363</fpage>
<lpage>4369</lpage><pub-id pub-id-type="pmid">15972531</pub-id></element-citation></ref><ref id="R12"><label>12.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Kebaier</surname><given-names>C</given-names></name><name><surname>Vanderberg</surname><given-names>J</given-names></name></person-group>
<year>2007</year>
<article-title>Direct microscopic quantification of dynamics of <italic>Plasmodium berghei</italic> sporozoite transmission from mosquitoes to mice</article-title>
<source>Infect Immun</source>
<volume>75</volume>
<fpage>5532</fpage>
<lpage>5539</lpage><pub-id pub-id-type="pmid">17785479</pub-id></element-citation></ref><ref id="R13"><label>13.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ploemen</surname><given-names>IH</given-names></name><name><surname>Chakravarty</surname><given-names>S</given-names></name><name><surname>van Gemert</surname><given-names>GJ</given-names></name><name><surname>Annoura</surname><given-names>T</given-names></name><name><surname>Khan</surname><given-names>SM</given-names></name><name><surname>Janse</surname><given-names>CJ</given-names></name><name><surname>Hermsen</surname><given-names>CC</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name><name><surname>Sauerwein</surname><given-names>RW</given-names></name></person-group>
<year>2013</year>
<article-title><italic>Plasmodium</italic> liver load following parenteral sporozoite administration in rodents</article-title>
<source>Vaccine</source>
<volume>31</volume>
<fpage>3410</fpage>
<lpage>3416</lpage><pub-id pub-id-type="pmid">23063834</pub-id></element-citation></ref></ref-list></back></article>